Intra-Cellular Therapies (ITCI) Named Top Pick at SunTrust Robinson Humphrey (Monday)

In a note to clients Monday, SunTrust Robinson Humphrey analyst Edward Nash named Intra-Cellular Therapies (NASDAQ: ITCI) the Top Pick in their coverage universe. The firm also reiterated a Buy rating and price target of $60.

"We believe Intra-Cellular has the potential to offer investors significant upside over the next 12 months with its de-risked lead clinical program targeting a market that provides significant revenue potential," Nash said.

He added, "Moreover, the unique mechanism of action of the product candidate, which has been well characterized by Intra-Cellular, provides the compound with versatility to be developed for multiple follow-on indications."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $26.06 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
• Freedom Broker Starts Citizens Inc. (CIA) at Buy
• Vivmark Residential (VMRK) PT Lowered to $74 at BMO Capital